A high-conviction short opportunity is identified in InMune Bio (INMB), with expectations of a 90% stock drop following its upcoming Alzheimer's trial data release. Conversely, Sarepta Therapeutics (SRPT) is a strong long-term buy, with its limb-girdle muscular dystrophy (LGMD) gene therapy pipeline viewed as a major, underappreciated catalyst. The analyst is also actively shorting speculative stocks BigBear.ai (BBAI), IonQ (IONQ), and D-Wave Quantum (QBTS), believing they are fundamentally flawed. For a potential long idea, Madrigal Pharmaceuticals (MDGL) was mentioned favorably and is worth further research. These event-driven biotech trades carry significant risk and investors should proceed with caution.

InMune Bio (INMB)

• The speaker is extremely bearish on INMB and is actively short the stock. He believes the company's upcoming Phase 2 Alzheimer's trial data will be negative and the stock will "drop 90% very soon."
• The core of the bearish thesis is that the drug's mechanism of action, targeting TNF-alpha, is flawed for treating Alzheimer's disease.
  • He argues that TNF-alpha is not a key driver of Alzheimer's and may even be protective. Stopping it could make the disease worse.
  • He points to numerous past failures of other anti-inflammatory drugs, including other TNF-alpha inhibitors, in Alzheimer's trials.
  • He questions whether the drug can effectively cross the blood-brain barrier to have an effect.
  • He criticizes the company's Phase 1 data as being "done very poorly" with no placebo group and inconclusive results on inflammation markers.
• The speaker notes the company is announcing results on a Monday with a conference call, which creates uncertainty. While some might see a conference call as a bullish sign, he notes that companies like Sarepta have also held calls for negative results. The lack of slides for the call is viewed as a bearish indicator.

Takeaways

• This is a high-risk, event-driven trade. The speaker has a strong conviction that INMB's lead drug for Alzheimer's will fail its clinical trial, with results expected on the upcoming Monday.
• The investment thesis is based on a deep, scientific critique of the drug's mechanism and the history of similar failed approaches in Alzheimer's research.
• Investors should be aware of the extreme bearish sentiment. The speaker believes the stock has a near-term downside of 90%. This implies a very high-risk, high-reward scenario for both bulls and bears leading into the data release.

Sarepta Therapeutics (SRPT)

• The speaker is bullish on SRPT and holds a large, concentrated position, stating "I have 10% of my portfolio in Serupto. That's pretty extreme."
• He is particularly excited about the potential of their limb-girdle muscular dystrophy (LGMD) gene therapy, believing the LGMD drug alone "could be worth more than the market cap right now."
• He acknowledges the stock has been "a bit of a dog" and a "painful journey" but remains long.
• He dismisses concerns about an FDA investigation into their drug Elevidis, comparing its risks to other accepted medical treatments like stem cell transplants.

Takeaways

• The speaker has a strong bullish conviction on SRPT, viewing it as a long-term holding with significant upside potential, primarily driven by its LGMD pipeline asset.
• This is a high-conviction bet, as evidenced by the 10% portfolio allocation.
• Investors might consider looking into Sarepta's LGMD program as a potential value driver that the market may be underappreciating.

Quantum Computing Stocks (IONQ, QBTS)

• IonQ (IONQ): The speaker is bearish, stating he has "been increasing my quantum shorts" and hasn't changed his mind that IONQ "has gone zero." He acknowledges they received a contract with Korea but also calls the stock "a bit of a dog."
• D-Wave Quantum (QBTS): The speaker is also bearish, describing the stock as "falling like a rock" and a "fake company, fake news." He points to its recent price action, noting it was down 12 out of the last 13 trading sessions.

Takeaways

• The speaker holds a negative view on the quantum computing sector, specifically mentioning short positions.
• He believes these companies are overvalued or fundamentally flawed, suggesting investors should be cautious or consider them as potential short opportunities. The technical trend for QBTS is noted as being extremely weak.

BigBear.ai (BBAI)

• The speaker is extremely bearish on BBAI.
• He explicitly advises listeners: "You should be short B-buy. Don't be long B-buy. Stop the suffering."
• He believes the company is "kind of a scam" and a "bad stock," lumping it in with other speculative WallStreetBets/Reddit stocks that he thinks are almost universally poor investments.

Takeaways

• There is a strong, direct recommendation to short BBAI or at least avoid being long the stock.
• The sentiment is based on the perception that it's a low-quality, speculative company popular with retail traders, which the speaker views as a negative indicator.

Other Mentioned Stocks

• Nektar Therapeutics (NKTR): The speaker notes that the management team has a poor track record but "finally did something right." A partner of his was long the stock and did well. The recent positive outcome after announcing a Monday conference call is seen as a potential (though not guaranteed) parallel for the INMB situation.
• Altimmune (ALT): The speaker has a very negative initial impression, calling their "positive top line results" "Dog poo-poo." However, he admits he has not looked at the data in detail yet.
• Madrigal Pharmaceuticals (MDGL): Mentioned briefly as a stock that the speaker likes.
• CRISPR Stocks: The speaker believes the underlying CRISPR technology is "real" but "not that useful yet." He implies the sector may be ahead of itself and that specific companies are just one of many competitors.

Takeaways

• NKTR serves as a recent example of a biotech stock with a similar news announcement pattern to INMB that had a positive outcome, creating some speculative excitement.
• Initial sentiment on ALT is highly negative, suggesting skepticism is warranted despite positive company headlines.
• MDGL is a name to note for potential further research, given the positive mention.
• Investors in the CRISPR space should be aware that while the technology is promising, its practical application and commercial viability may still be far off, and the field is crowded.

General Investment Philosophy

• Expect to be wrong: The speaker states that "50% of your stock picks are gonna be wrong." The key is to have a process and not get emotionally attached or "marry any specific stock." Doubling down on losers is a path to ruin.
• Biotech investing is difficult: He notes that at least half of all academic literature is "worthless," making it hard to rely on early research. Acquisitions are also not a common exit strategy to rely on.
• Avoid options unless necessary: He describes using options when you don't need to as "just asking yourself to make the shot harder." He is short INMB via the stock itself, not through puts.

Takeaways

• Portfolio management is key. Since half of your ideas may be wrong, it's crucial to manage risk and cut losers rather than adding to them.
• Investors in the biotech space need to be highly skeptical and do their own deep due diligence, as academic papers and acquisition hopes can be misleading.
• For most investors, direct stock ownership is a simpler and potentially safer way to express an investment thesis compared to the complexity and time-decay of options.